| Donahoe, Michael |
| Active, not recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo | Savara Inc., Savara ApS, | Autoimmune Pulmonary Alveolar Proteinosis | 06/24 | 06/25 | | |
| Corcoran, Timothy E |
NCT05755932: Study to Assess Effect of HFO MDI Propellant on Mucociliary Clearance Compared to HFA MDI Propellant in Healthy Participants |
|
|
| Recruiting | 3 | 30 | US | HFO MDI, Propellant in MDI, HFA MDI | AstraZeneca | Mucociliary Clearance | 07/24 | 07/24 | | |
| Chan, Stephen L |
SIERRA, NCT05883644: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 3 | 110 | Europe, Japan, US, RoW | Durvalumab, Tremelimumab | AstraZeneca | Advanced Hepatocellular Carcinoma | 06/25 | 12/25 | | |
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer |
|
|
| Recruiting | 2/3 | 780 | Europe | Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin | Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK | Breast Cancer | 06/24 | 06/34 | | |
| Completed | 2 | 24 | RoW | SIRT Yttrium-90 | Chinese University of Hong Kong | Cholangio Carcinoma | 01/23 | 02/23 | | |
| Active, not recruiting | 2 | 30 | RoW | pembrolizumab | CCTU | HCC | 12/24 | 12/25 | | |
NCT05378048: Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors |
|
|
| Withdrawn | 2 | 140 | RoW | PDO-guided treatment, standard of care | Chinese University of Hong Kong | Organoids | 07/25 | 07/25 | | |
| Recruiting | 2 | 44 | RoW | Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib | Stephen Chan Lam | HCC | 12/26 | 12/27 | | |
| Recruiting | 1 | 71 | US | 18F-FGLN PET Imaging, (18F)FPGLU | Stephen Y. Chan, Bayer, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Arterial Hypertension | 12/24 | 12/25 | | |
NCT04649866: Coronary Artery Disease in Patients With Friedreich's Ataxia |
|
|
| Completed | N/A | 7 | US | plethysmography | University of Pittsburgh, Friedreich's Ataxia Research Alliance | Friedreich Ataxia | 08/23 | 09/23 | | |
NCT02594917: Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension |
|
|
| Completed | N/A | 13 | US | Right Heart Catheterization, Blood draw | University of Pittsburgh | Iron-sulfur Cluster Deficiency, Pulmonary Hypertension, Friedreich Ataxia | 09/23 | 09/23 | | |
| Active, not recruiting | N/A | 207 | RoW | Fibroscan | Chinese University of Hong Kong | Confirmed Diagnosis of Hepatocellular Carcinoma, Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery, Child's A to C Cirrhosis | 12/25 | 12/26 | | |
| Recruiting | N/A | 3000 | US | | Pulmonary Hypertension Association, Inc., University of Washington, the Collaborative Health Studies Coordinating Center | Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension | 10/25 | 10/25 | | |
| Aaraj, Yassmin Al |
| Recruiting | 1 | 71 | US | 18F-FGLN PET Imaging, (18F)FPGLU | Stephen Y. Chan, Bayer, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Arterial Hypertension | 12/24 | 12/25 | | |
NCT04649866: Coronary Artery Disease in Patients With Friedreich's Ataxia |
|
|
| Completed | N/A | 7 | US | plethysmography | University of Pittsburgh, Friedreich's Ataxia Research Alliance | Friedreich Ataxia | 08/23 | 09/23 | | |
